IN8bio (NASDAQ:INAB) Earns “Buy” Rating from HC Wainwright

IN8bio (NASDAQ:INAB)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They currently have a $8.00 price target on the stock.

IN8bio Price Performance

Shares of NASDAQ:INAB opened at $0.31 on Wednesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.84 and a current ratio of 1.84. The firm has a market cap of $22.24 million, a price-to-earnings ratio of -0.41 and a beta of 0.05. The business has a 50-day simple moving average of $0.28 and a two-hundred day simple moving average of $0.36. IN8bio has a fifty-two week low of $0.22 and a fifty-two week high of $1.74.

IN8bio (NASDAQ:INAB) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). On average, analysts expect that IN8bio will post -0.56 earnings per share for the current year.

Institutional Investors Weigh In On IN8bio

A hedge fund recently raised its stake in IN8bio stock. Sigma Planning Corp increased its position in IN8bio, Inc. (NASDAQ:INAB) by 22.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,041,380 shares of the company’s stock after acquiring an additional 190,100 shares during the period. Sigma Planning Corp owned about 1.44% of IN8bio worth $268,000 at the end of the most recent reporting period. 92.05% of the stock is owned by institutional investors.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.